AMENDMENT

Subject matter to be added is in bold and underlined.

Subject matter to be deleted is in bold and strikethrough.

In the Claims:

Please amend Claims 1-3 and enter new claims 24-43 as follows. Please withdraw Claims 11-12 and cancel Claims 15-23 without prejudice to presentation in a Divisional or Continuation application.

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently amended) A compound of Formula (I):



(I)

or a stereoisomer or a pharmaceutically acceptable salt or hydrate thereof, wherein:

L_1 is a bond~~, $-CH_2-$, $-CH_2CH_2-$, $-CH_2O-$, $-CH_2S(O)_p-$, $-CH_2NR^{10}-$, $-CH_2C(O)-$, or $-CONR^{10}-$~~;

L_2 is a bond, ~~$-(CR^6R^{6a})_{1-2}-$~~, $\underline{-CH_2-, \text{ or } -O-}$, ~~$-NR^{10}-$, $-C(O)-$, $-S(O)_p-$, $-(CR^6R^{6a})C(O)-$, $-C(O)(CR^6R^{6a})-$, $-(CR^6R^{6a})O-$, $-O(CR^6R^{6a})-$, $-(CR^6R^{6a})NR^{10}-$, $-NR^{10}(CR^6R^{6a})-$, $-(CR^6R^{6a})S(O)_p-$, $-S(O)_p(CR^6R^{6a})-$, $-C(O)O-$, $-OC(O)-$, $-C(O)NR^8-$, $-NR^8C(O)-$, $-S(O)NR^8-$, $-S(O)_2NR^8-$, $-NR^8S(O)-$, or $-NR^8S(O)_2-$~~;

A is ~~C_{3-10} carbocycle~~ $\underline{\text{phenyl}}$ substituted with 0-3 R^{11} and 0-1 R^{12}~~, or a 5-12 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted 0-3 R^{11} and 0-1 R^{12}~~;

B is ~~C_{1-6} alkyl substituted with 0-2 R^{11} and 0-1 R^{12}, C_{2-6} alkenyl substituted with 0-2 R^{11} and 0-1 R^{12}, C_{2-6} alkynyl substituted with 0-2 R^{11} and 0-1 R^{12}, C_{3-10} carbocycle~~ phenyl substituted with 0-3 R^{11} and 0-1 R^{12}~~, or a 5-12 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted with 0-3 R^{11} and 0-1 R^{12}~~;

X^1, X^2, X^3 and X^4 independently represent CR^1, CR^2, or CR^3 ~~or N~~;

R^1 is H, $-NH_2$, $-NH(C_1-C_3$ alkyl), $-N(C_1-C_3$ alkyl$)_2$, $-C(=NH)NH_2$, $-NHC(=NH)NH_2$, $-C(O)NH_2$, $-CH_2NH_2$, $-CH_2NH(C_1-C_3$ alkyl), $-CH_2N(C_1-C_3$ alkyl$)_2$, $-CH_2CH_2NH_2$, $-CH_2CH_2NH(C_1-C_3$ alkyl), $-CH_2CH_2N(C_1-C_3$ alkyl$)_2$, $-C(=NR^8)NR^7R^9$, $-NHC(=NR^8)NR^7R^9$, $-ONHC(=NR^8)NR^7R^9$, $-NR^8CH(=NR^7)$, $-C(=NR^{8a})NR^7R^9$, $-NHC(=NR^{8a})NR^7R^9$, $-NR^7R^8$, $-C(O)NR^{7a}R^8$, $-S(O)_pNR^8R^9$, F, Cl, Br, I, OCF_3, CF_3, OR^a, SR^a, CN or C_{1-6} alkyl substituted with 1 R^{1a};

R^{1a} is $-C(=NR^8)NR^7R^9$, $-NHC(=NR^8)NR^7R^9$, $-ONHC(=NR^8)NR^7R^9$, $-NR^8CH(=NR^7)$, $-NR^7R^8$, $-C(O)NR^{7a}R^8$, $-S(O)_pNR^8R^9$, F, OCF_3, CF_3, OR^a, SR^a, or CN;

R^2 is H, F, Cl, Br, I, OCF_3, CF_3, OR^a, SR^a, CN, NO_2, $-NR^7R^8$, $-C(O)NR^{7a}R^8$, $-NR^{10}C(O)R^b$, $-S(O)_pNR^8R^9$, $-S(O)R^c$, $-S(O)_2R^c$, C_{1-6} alkyl substituted with 0-2 R^{2a}, C_{2-6} alkenyl substituted with 0-2 R^{2a}, C_{2-6} alkynyl substituted with 0-2 R^{2a}, or $-(CH_2)_r$-C_{3-10} carbocycle substituted with 0-3 R^{2b}~~, or $-(CH_2)_r$-5-10 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted with 0-3 R^{2b}~~;

each R^{2a} is, independently at each occurrence, H, F, OCF_3, CF_3, OR^a, SR^a, CN, $-NR^7R^8$, $-C(O)NR^{7a}R^8$, $-NR^{10}C(O)R^b$, $-S(O)_pNR^8R^9$, $-S(O)R^c$, or $-S(O)_2R^c$;

each R^{2b} is, independently at each occurrence, H, F, Cl, Br, I, OR^a, SR^a, CN, NO_2, CF_3, $-SO_2R^c$, $-NR^7R^8$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl, C_{1-4} haloalkyl, C_{1-4} haloalkyloxy-, C_{1-4} alkyloxy-, C_{1-4} alkylthio-, C_{1-4} alkyl-C(O)-, or C_{1-4} alkyl-C(O)NH-;

alternately, when R^1 and R^2 are substituted on adjacent ring carbon atoms, they can be taken together with the ring carbon atoms to which they are attached to form a 5-7 membered carbocycle ~~**or heterocycle**~~ substituted with 0-2 R^{2b};

R^3 is H, F, Cl, Br, I, OCF_3, CF_3, OR^a, SR^a, CN, NO_2, $-NR^7R^8$, $-C(O)NR^{7a}R^8$, $-NR^{10}C(O)R^b$, $-S(O)_pNR^8R^9$, $-S(O)R^c$, $-S(O)_2R^c$, C_{1-6} alkyl substituted with 0-2 R^{3a}, C_{2-6} alkenyl substituted with 0-2 R^{3a}, C_{2-6} alkynyl substituted with 0-2 R^{3a}, **or** $-(CH_2)_r$-C_{3-10} carbocycle substituted with 0-3 R^{3b}~~**, or $-(CH_2)_r$-5-10 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted with 0-3 R^{3b}**~~;

each R^{3a} is, independently at each occurrence, H, F, OCF_3, CF_3, OR^a, SR^a, CN, $-NR^7R^8$, $-C(O)NR^{7a}R^8$, $-NR^{10}C(O)R^b$, $-S(O)_pNR^8R^9$, $-S(O)R^c$, or $-S(O)_2R^c$;

each R^{3b} is, independently at each occurrence, H, F, Cl, Br, I, OR^a, SR^a, CN, NO_2, CF_3, $-SO_2R^c$, $-NR^7R^8$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl, C_{1-4} haloalkyl, C_{1-4} haloalkyloxy-, C_{1-4} alkyloxy-, C_{1-4} alkylthio-, C_{1-4} alkyl-C(O)-, or C_{1-4} alkyl-C(O)NH-;

R^4 is ~~**H, F, OR^a, SR^a, $-NR^7R^8$, $-NR^{10}C(O)NR^{7a}R^8$, $-NR^{10}SO_2R^e$, $-C(O)OR^a$, $-C(O)NR^{7a}R^8$, C_{1-4} haloalkyl, C_{1-6} alkyl substituted with 0-3 R^{4a}, C_{2-6} alkenyl substituted with 0-3 R^{4a}, C_{2-6} alkynyl substituted with 0-3 R^{4a}, $-(CH_2)_r$-C_{3-10} carbocycle**~~ **phenyl** substituted with 0-3 R^{4b}~~**, or $-(CH_2)_r$-5-10 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted with 0-3 R^{4b}**~~;

~~**each R^{4a} is, independently at each occurrence, H, C_{1-4} alkyl, OR^a, F, =O, CF_3, CN, $-C(O)R^a$, $-C(O)OR^a$, $-C(O)NR^{7a}R^8$, $-NR^{10}COR^e$, or $-S(O)_pR^b$;**~~

each R^{4b} is, independently at each occurrence, H, OH, Cl, F, Br, I, CN, NO_2, CF_3, $-C(O)OR^a$, $-SO_2R^c$, $-NR^7R^8$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl, C_{1-4} haloalkyl, C_{1-4} haloalkyloxy-, C_{1-4} alkyloxy-, C_{1-4} alkylthio-, C_{1-4} alkyl-C(O)-, C_{1-4} alkyl-C(O)NH-, $-C(O)NR^{7a}R^8$, $-NR^{10}C(O)R^b$, $-NR^{10}S(O)_2NR^8R^9$, or $-S(O)_2NR^8R^9$;

R^5 is H, ~~F,~~ C_{1-4} haloalkyl, or C_{1-6} alkyl substituted with 0-3 R^{5a}~~, C_{2-6} alkenyl substituted with 0-3 R^{5a}, C_{2-6} alkynyl substituted with 0-3 R^{5a}, $(CH_2)_r$ C_{3-10} carbocycle substituted with 0-3 R^{5b}, or $(CH_2)_r$ 5-10 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted with 0-3 R^{5b}~~;

each R^{5a} is, independently at each occurrence, H, C_{1-4} alkyl, OR^a, F, =O, CF_3, CN, $-C(O)R^a$, $-C(O)OR^a$, $-C(O)NR^{7a}R^8$, or $-S(O)_pR^c$;

~~each R^{5b} is, independently at each occurrence, H, OH, Cl, F, Br, I, CN, NO_2, CF_3, $-C(O)OR^a$, $-SO_2R^e$, $-NR^7R^8$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl, C_{1-4} haloalkyl, C_{1-4} haloalkyloxy-, C_{1-4} alkyloxy-, C_{1-4} alkylthio-, C_{1-4} alkyl-C(O)-, or C_{1-4} alkyl-C(O)NH-;~~

each R^6 is, independently at each occurrence, H, C_{1-4} alkyl, $-(CH_2)_rC(O)OR^a$, $-(CH_2)_rS(O)_2NR^{7a}R^8$, or $-(CH_2)_rOR^a$;

each R^{6a} is, independently at each occurrence, H or C_{1-4} alkyl;

each R^7 is, independently at each occurrence, H, C_{1-6} alkyl, $-(CH_2)_n$-phenyl, (C_{1-6} alkyl)C(O)-, (C_{6-10} aryl)-C_{0-4} alkyl-C(O)-, (C_{3-6} cycloalkyl)-C_{0-4} alkyl-C(O)-, ~~(5-10 membered heteroaryl)-C_{0-4} alkyl-C(O)-,~~ (C_{1-4} alkyl)OC(O)-, (C_{6-10} aryl)-C_{0-4} alkyl-OC(O)-, (C_{1-4} alkyl)-C(O)O-(C_{1-4} alkyl)-OC(O)-, (C_{6-10} aryl)-C(O)O-(C_{1-4} alkyl)-OC(O)-, ~~(5-10 membered heteroaryl)-CH_2-OC(O)-,~~ (C_{1-6} alkyl)-NHC(O)-, (C_{6-10} aryl)-C_{0-4} alkyl-NHC(O)-, ~~(5-10 membered heteroaryl)-C_{0-4} alkyl-NHC(O)-,~~ (C_{1-6} alkyl)-$S(O)_2$-, (C_{6-10} aryl)-(C_{0-4} alkyl)-$S(O)_2$-, ~~(5-10 membered heteroaryl)-C_{0-4} alkyl-$S(O)_2$-,~~ (C_{1-6} alkyl)$_2$NC(O)-, phenyl-NHC(O)-, benzyl-NHC(O)-, (phenyl)(C_{1-6} alkyl)NC(O)-, or (benzyl)(C_{1-6} alkyl)NC(O)-, wherein said phenyl~~,~~ **and** aryl ~~and heteroaryl~~ are substituted with 0-2 R^f;

each R^{7a} is, independently at each occurrence, H, C_{1-4} alkyl substituted with 0-2 R^{7b} or 0-2 R^{7c}, or $-(CH_2)_r$-C_{3-10} carbocycle substituted with 0-3 R^f~~, or a $-(CH_2)_r$ 5-12~~

~~membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted 0-3 R^f~~;

each R^{7b} is, independently at each occurrence, =O, OR^g, F, Cl, Br, I, CN, NO_2, $-NR^7R^8$, $-C(O)R^g$, $-C(O)OR^g$, $-NR^8C(O)R^g$, $-C(O)NR^8R^9$, $-NR^8C(O)NR^8R^9$, $-SO_2NR^8R^9$, $-NR^8SO_2NR^8R^9$, $-NR^8SO_2$-C_{1-4} alkyl, $-NR^8SO_2CF_3$, $-NR^8SO_2$-phenyl, $-S(O)_2CF_3$, $-S(O)_p$-C_{1-4} alkyl, $-S(O)_p$-phenyl, or $-(CF_2)_rCF_3$;

each R^{7c} is~~, independently at each occurrence,~~ C_{3-10} carbocycle substituted with 0-3 R^f; ~~or a 5-12 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted 0-3 R^f;~~

each R^8 is, independently at each occurrence, H, C_{1-6} alkyl, or $-(CH_2)_n$-phenyl;

each R^{8a} is, independently at each occurrence, H, OH, C_{1-6} alkyl, $-(CH_2)_n$-phenyl, (C_{1-6} alkyl)C(O)-, (C_{6-10} aryl)-C_{0-4} alkyl-C(O)-, (C_{3-6} cycloalkyl)-C_{0-4} alkyl-C(O)-, ~~(5-10 membered heteroaryl)-C_{0-4} alkyl-C(O)-,~~ (C_{1-4} alkyl)OC(O)-, (C_{6-10} aryl)-C_{0-4} alkyl-OC(O)-, (C_{1-4} alkyl)-C(O)O-(C_{1-4} alkyl)-OC(O)-, (C_{6-10} aryl)-C(O)O-(C_{1-4} alkyl)-OC(O)-, ~~(5-10 membered heteroaryl)-CH_2-OC(O)-,~~ (C_{1-6} alkyl)-NHC(O)-, (C_{6-10} aryl)-C_{0-4} alkyl-NHC(O)-, ~~(5-10 membered heteroaryl)-C_{0-4} alkyl-NHC(O)-,~~ (C_{1-6} alkyl)-$S(O)_2$-, (C_{6-10} aryl)-(C_{0-4} alkyl)-$S(O)_2$-, ~~(5-10 membered heteroaryl)-C_{0-4} alkyl-$S(O)_2$-,~~ C_{1-4} alkoxy, (C_{1-4} alkyl)C(O)O-, or (C_{6-10} aryl)-(C_{0-4} alkyl)-C(O)O-; wherein said phenyl~~,~~ **and** aryl ~~and heteroaryl~~ are substituted with 0-2 R^f;

~~alternatively, R^7 and R^8, or R^{7a} and R^8, when attached to the same nitrogen, combine to form a 5-10 membered heterocyclic ring consisting of carbon atoms and 0-2 additional heteroatoms selected from the group consisting of N, O, and $S(O)_p$;~~

each R^9 is, independently at each occurrence, H, C_{1-6} alkyl, or $-(CH_2)_n$-phenyl;

each R^{10} is, independently at each occurrence, H, C_{1-6} alkyl substituted with 0-2 R^{10a}, C_{2-6} alkenyl substituted with 0-2 R^{10a}, C_{2-6} alkynyl substituted with 0-2 R^{10a}, (C_{1-6} alkyl)C(O)-, (C_{3-6} cycloalkyl)C_{1-3} alkyl-C(O)-, (C_{3-6} cycloalkyl)C(O)-, phenyl-C(O)-, benzyl-C(O)-, benzyl-$S(O)_2$-, (C_{1-6} alkyl)NHC(O)-, (C_{1-6} alkyl)$_2$NC(O)-, phenyl-NHC(O)-, benzyl-NHC(O)-, (phenyl)(C_{1-6} alkyl)NC(O)-, (benzyl)(C_{1-6} alkyl)NC(O)-, (C_{1-6} alkyl)-$S(O)_2$-, phenyl-$S(O)_2$-, **or** -$(CH_2)_r$-C_{3-10} carbocycle substituted with 0-3 R^d~~, or -$(CH_2)_r$- 5-10 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted with 0-3 R^d~~;

each R^{10a} is, independently at each occurrence, H, C_{1-4} alkyl, OR^a, Cl, F, Br, I, =O, CF_3, CN, NO_2, -C(O)R^a, -C(O)OR^a, -C(O)$NR^{7a}R^8$, or -$S(O)_pR^c$;

each R^{11} is, independently at each occurrence, H, =O, -$(CH_2)_r$-OR^a, F, Cl, Br, I, CN, NO_2, -$(CH_2)_r$-NR^7R^8, -C(O)R^a, -C(O)OR^a, -NR^8C(O)R^a, -NR^8C(O)OR^a, -C(O)$NR^{7a}R^8$, -NR^8C(O)NR^8R^9, -$SO_2NR^8R^9$, -$NR^8SO_2NR^8R^9$, -NR^8SO_2-C_{1-4} alkyl, -$NR^8SO_2CF_3$, -NR^8SO_2-phenyl, -$S(O)_2CF_3$, -$S(O)_p$-C_{1-4} alkyl, -$S(O)_p$-phenyl, -$(CF_2)_rCF_3$, C_{1-6} alkyl substituted with 0-2 R^{11a}, C_{2-6} alkenyl substituted with 0-2 R^{11a}, C_{2-6} alkynyl substituted with 0-2 R^{11a}, C_{1-6} alkyl substituted with 0-2 R^{11b}, C_{2-6} alkenyl substituted with 0-2 R^{11b}, or C_{2-6} alkynyl substituted with 0-2 R^{11b};

each R^{11a} is, independently at each occurrence, =O, OR^a, F, Cl, Br, I, CN, NO_2, -NR^7R^8, -C(O)R^a, -C(O)OR^a, -NR^8C(O)R^a, -C(O)$NR^{7a}R^8$, -NR^8C(O)NR^8R^9, -$SO_2NR^8R^9$, -$NR^8SO_2NR^8R^9$, -NR^8SO_2-C_{1-4} alkyl, -$NR^8SO_2CF_3$, -NR^8SO_2-phenyl, -$S(O)_2CF_3$, -$S(O)_p$-C_{1-4} alkyl, -$S(O)_p$-phenyl, or -$(CF_2)_rCF_3$;

each R^{11b} is, independently at each occurrence, C_{3-10} carbocycle substituted with 0-3 R^d; or a 5-12 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted 0-3 R^d;

each R^{12} is, independently at each occurrence, OR^{12a}, -C(O)$NR^{7a}R^8$, -$(CH_2)_rCO_2R^{12a}$, -$(CH_2)_rSO_3H$, -OSO_3H, -$(CH_2)_rPO_3H$, -OPO_3H_2, -PO_3H_2,

$-NHPO_3H_2$, $-NHCOCF_3$, $-NHSO_2CF_3$, $-CONHNHSO_2CF_3$, $-C(CF_3)_2OH$, $-SO_2NHR^{12a}$, $-CONHSO_2NHR^{12a}$, $-SO_2NHCOR^{12a}$, $-SO_2NHCO_2R^{12a}$, $-CONHSO_2R^{12b}$, $-NHSO_2R^{12b}$, $-CONHOR^{12b}$,





or

;

each R^{12a} is, independently at each occurrence, H, $C_{1\text{-}6}$ alkyl, $-(CH_2)_r\text{-}C_{3\text{-}10}$ carbocycle substituted with 0-3 R^d; or $-(CH_2)_r$-5-10 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted with 0-3 R^d;

each R^{12b} is, independently at each occurrence, $C_{1\text{-}6}$ alkyl substituted with 0-2 R^{12c}, $C_{2\text{-}6}$ alkenyl substituted with 0-2 R^{12c}, $C_{2\text{-}6}$ alkynyl substituted with R^{12c}, $-(CH_2)_r\text{-}C_{3\text{-}10}$ carbocycle substituted with 0-3 R^{12c}, or $-(CH_2)_r$-5-10 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted with 0-3 R^{12c};

each R^{12c} is, independently at each occurrence, H, F, Cl, Br, I, CF_3, OCF_3, CN, NO_2, OR^a, $-CO_2R^a$, $-NR^7R^8$, $-SO_2R^c$, $C_{1\text{-}6}$ alkyl, $C_{2\text{-}6}$ alkenyl, $C_{2\text{-}6}$ alkynyl, $-(CH_2)_r\text{-}C_{3\text{-}10}$ carbocycle substituted with 0-3 R^d; or $-(CH_2)_r$-5-10 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted with 0-3 R^d;

R^{13} is H, $C_{1\text{-}4}$ alkyl, $(NR^7R^8)C_{1\text{-}4}$ alkyl, $(SR^c)C_{1\text{-}4}$ alkyl, $(OR^a)C_{1\text{-}4}$ alkyl, OR^a, F, CF_3, $-C(O)R^a$, $-C(O)OR^a$, $-C(O)NR^{7a}R^8$, or $-S(O)_pR^c$;

R^{14} is H, $C_{1\text{-}4}$ alkyl, $(NR^7R^8)C_{1\text{-}4}$ alkyl, $(SR^c)C_{1\text{-}4}$ alkyl, $(OR^a)C_{1\text{-}4}$ alkyl, OR^a, F, CF_3, $-C(O)R^a$, $-C(O)OR^a$, $-C(O)NR^{7a}R^8$, or $-S(O)_pR^c$;

alternately, R^{13} and R^{14} may be taken together to be =O;

R^{15} is H or C_{1-4} alkyl;

R^{16} is H, C_{1-4} alkyl, benzyl, C_{1-4} alkyl-C(O)-, C_{1-4} alkyl-$S(O)_2$-, or C_{1-4} alkyl-OC(O)-;

each R^a is, independently at each occurrence, H, C_{1-4} alkyl, -$(CH_2)_r$-CO_2R^g, -$(CH_2)_r$-C_{3-7} cycloalkyl, **or** -$(CH_2)_r$-C_{6-10} aryl, ~~**or -$(CH_2)_r$-5-10 membered heteroaryl,**~~ wherein said aryl ~~**or heteroaryl groups are**~~ **is** substituted with 0-2 R^f;

each R^b is, independently at each occurrence, CF_3, OH, C_{1-4} alkoxy, C_{1-6} alkyl, **or** -$(CH_2)_r$-C_{3-10} carbocycle substituted with 0-2 R^d~~**, or -$(CH_2)_r$-5-10 membered heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$ and substituted with 0-2 R^d**~~;

each R^c is, independently at each occurrence, C_{1-4} alkyl, C_{6-10} aryl, **or** ~~**5-10 membered heteroaryl,**~~ (C_{6-10} aryl)-C_{1-4} alkyl, ~~**or (5-10 membered heteroaryl)-C_{1-4} alkyl,**~~ wherein said aryl ~~**and heteroaryl groups are**~~ **is** substituted with 0-2 R^d;

each R^d is, independently at each occurrence, H, =O, OR^a, F, Cl, Br, I, CN, NO_2, -NR^7R^8, -$C(O)R^a$, -$C(O)OR^a$, -$NR^8C(O)R^a$, -$C(O)NR^{7a}R^8$, -$SO_2NR^8R^9$, -$NR^8SO_2NR^8R^9$, -NR^8SO_2-C_{1-4} alkyl, -$NR^8SO_2CF_3$, -NR^8SO_2-phenyl, -$S(O)_2CF_3$, -$S(O)_p$-C_{1-4} alkyl, -$S(O)_p$-phenyl, -$(CF_2)_rCF_3$, C_{1-6} alkyl substituted with 0-2 R^e, C_{2-6} alkenyl substituted with 0-2 R^e, or C_{2-6} alkynyl substituted with 0-2 R^e;

each R^e is, independently at each occurrence, =O, OR^a, F, Cl, Br, I, CN, NO_2, -NR^8R^9, -$C(O)R^a$, -$C(O)OR^a$, -$NR^8C(O)R^a$, -$C(O)NR^{7a}R^8$, -$SO_2NR^8R^9$, -$NR^8SO_2NR^8R^9$, -NR^8SO_2-C_{1-4} alkyl, -$NR^8SO_2CF_3$, -NR^8SO_2-phenyl, -$S(O)_2CF_3$, -$S(O)_p$-C_{1-4} alkyl, -$S(O)_p$-phenyl, or -$(CF_2)_rCF_3$;

each R^f is, independently at each occurrence, H, =O, OR^g, F, Cl, Br, I, CN, NO_2, -NR^8R^9, -$C(O)R^g$, -$C(O)OR^g$, -$NR^8C(O)R^g$, -$C(O)NR^8R^9$, -$SO_2NR^8R^9$, -$NR^8SO_2NR^8R^9$, -NR^8SO_2-C_{1-4} alkyl, -$NR^8SO_2CF_3$, -NR^8SO_2-phenyl, -$S(O)_2CF_3$, -$S(O)_p$-C_{1-4} alkyl, -$S(O)_p$-phenyl, -$(CF_2)_rCF_3$, C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl;

each R^g is, independently at each occurrence, H, C_{1-6} alkyl, or

-$(CH_2)_n$-phenyl;

n, at each occurrence, is selected from 0, 1, 2, 3, and 4;

p, at each occurrence, is selected from 0, 1, and 2;

r, at each occurrence, is selected from 0, 1, 2, 3, and 4; and

provided that when L_1 is a bond and A is phenyl or a 6-membered aromatic N-heterocycle, then ring A is not substituted ortho to L_1 with OH, halogen, -CO_2H, -C(O)O-C_{1-4} alkyl, -O-phenyl, -O-benzyl, -NR^7R^8, -CH_2OR^a, haloalkyl, -S-C_{1-4} alkyl, or -$NHSO_2$-C_{1-4} alkyl.

2. (Currently amended) A compound according to Claim 1, wherein the compound is of Formula (Ia):



(Ia)

or a stereoisomer or a pharmaceutically acceptable salt or hydrate thereof, wherein:

~~L_2 is a bond, $(CR^6R^{6a})_{1-2}$, -O-, $-NR^{10}$-, -C(O)-, $-S(O)_p$-, $-CR^6R^{6a}C(O)$-, $-C(O)(CR^6R^{6a})$-, $(CR^6R^{6a})O$-, $O(CR^6R^{6a})$-, $(CR^6R^{6a})NR^{10}$-, $-NR^{10}(CR^6R^{6a})$-, $(CR^6R^{6a})S(O)_p$-, $-S(O)_p(CR^6R^{6a})$-, -C(O)O-, -OC(O)-, -C(O)NR^8-, $-NR^8C(O)$-, $-S(O)NR^8$-, $-S(O)_2NR^8$-, $-NR^8S(O)$-, or $-NR^8S(O)_2$-;~~

A is phenyl substituted with 0-2 R^{11} and 0-1 R^{12}~~, or a 5-12 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted 0-2 R^{11} and 0-1 R^{12}~~;

B is phenyl substituted with 0-2 R^{11} and 0-1 R^{12}~~, or a 5-12 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted with 0-2 R^{11} and 0-1 R^{12}~~;

R^1 is H, -NH_2, -NH(C_1-C_3 alkyl), -N(C_1-C_3 alkyl)$_2$, -C(=NH)NH_2,

-NHC(=NH)NH_2, -C(O)NH_2, -CH_2NH_2, -$CH_2NH(C_1$-C_3 alkyl), -$CH_2N(C_1$-C_3 alkyl)$_2$, -$CH_2CH_2NH_2$, -$CH_2CH_2NH(C_1$-C_3 alkyl), -$CH_2CH_2N(C_1$-C_3 alkyl)$_2$, -C(=NR^8)NR^7R^9, -NHC(=NR^8)NR^7R^9, -ONHC(=NR^8)NR^7R^9, -NR^8CH(=NR^7), -C(=NR^{8a})NR^7R^9, -NHC(=NR^{8a})NR^7R^9, -NR^7R^8, -C(O)$NR^{7a}R^8$, -$S(O)_pNR^8R^9$, F, Cl, Br, I, OCF_3, CF_3, OR^a, SR^a, CN or C_{1-6} alkyl substituted with 1 R^{1a};

R^{1a} is -C(=NR^8)NR^7R^9, -NHC(=NR^8)NR^7R^9, -ONHC(=NR^8)NR^7R^9, -NR^8CH(=NR^7), -NR^7R^8, -C(O)$NR^{7a}R^8$, -$S(O)_pNR^8R^9$, F, OCF_3, CF_3, OR^a, SR^a, or CN;

R^2 is H, F, OR^a, CN, -NR^7R^8, -C(O)$NR^{7a}R^8$, -$NR^{10}C(O)R^b$, -$S(O)_pNR^8R^9$, -S(O)R^c, -$S(O)_2R^c$, C_{1-6} alkyl substituted with 0-2 R^{2a}, **or** -$(CH_2)_r$-C_3-C_7 carbocycle substituted with 0-2 R^{2b}~~, or -$(CH_2)_r$-5-7 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted with 0-2 R^{2b}~~;

each R^{2a} is, independently at each occurrence, H, F, OCF_3, CF_3, OR^a, SR^a, CN, -NR^7R^8, -C(O)$NR^{7a}R^8$, -$NR^{10}C(O)R^b$, -$S(O)_pNR^8R^9$, -S(O)R^c, or -$S(O)_2R^c$;

each R^{2b} is, independently at each occurrence, H, F, OR^a, SR^a, CN, NO_2, CF_3, -SO_2R^c, -NR^7R^8, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, C_1-C_4 haloalkyl, C_1-C_4 haloalkyloxy-, C_1-C_4 alkyloxy-, C_1-C_4 alkylthio-, C_1-C_4 alkyl-C(O)-, or C_1-C_4 alkyl-C(O)NH-;

alternately, when R^1 and R^2 are substituted on adjacent ring carbon atoms, they can be taken together with the ring carbon atoms to which they are attached to form a 5-7 membered carbocycle ~~or heterocycle~~ substituted with 0-2 R^{2b};

R^4 is ~~H, C_1-C_4 haloalkyl, C_1-C_6 alkyl substituted with 0-3 R^{4a}, C_2-C_6 alkenyl substituted with 0-3 R^{4a}, C_2-C_6 alkynyl substituted with 0-3 R^{4a}, -$(CH_2)_r$-C_3-C_8 carbocycle~~ **phenyl** substituted with 0-3 R^{4b}~~, or -$(CH_2)_r$-5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted with 0-3 R^{4b}~~;

~~each R^{4a} is, independently at each occurrence, H, C_{1-4} alkyl, OR^a, F, =O, CF_3, CN, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^{7a}R^8$, $NR^{10}COR^c$, or $S(O)_pR^b$;~~

each R^{4b} is, independently at each occurrence, H, OH, Cl, F, Cl, Br, CN, NO_2, CF_3, $-C(O)OR^a$, $-SO_2R^c$, $-NR^7R^8$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, C_1-C_4 haloalkyl, C_1-C_4 haloalkyloxy-, C_1-C_4 alkyloxy-, C_1-C_4 alkylthio-, C_1-C_4 alkyl-C(O)-, C_1-C_4 alkyl-C(O)NH-, $-C(O)NR^{7a}R^8$, $-NR^{10}C(O)R^b$, $-NR^{10}S(O)_2NR^8R^9$, or $-S(O)_2NR^8R^9$;

R^5 is H, ~~F,~~ C_1-C_4 haloalkyl, or C_1-C_6 alkyl substituted with 0-2 ~~R^{5a},~~ ~~C_2-C_6 alkenyl substituted with 0-2 R^{5a}, C_2-C_6 alkynyl substituted with 0-2 R^{5a}, $-(CH_2)_r$-C_3-C_7 cycloalkyl substituted with 0-2 R^{5b}, $-(CH_2)_r$-phenyl substituted with 0-2 R^{5b}, or $-(CH_2)_r$-5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted with 0-2 R^{5b}~~;

~~R^{5a} is, independently at each occurrence, H, C_{1-4} alkyl, OR^a, F, =O, CF_3, CN, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^{7a}R^8$, or $S(O)_pR^e$;~~

~~each R^{5b} is, independently at each occurrence, H, OH, Cl, F, Br, CN, NO_2, CF_3, $C(O)OR^a$, SO_2R^e, NR^7R^8, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_6 cycloalkyl, C_1-C_4 haloalkyl, C_1-C_4 haloalkyloxy-, C_1-C_4 alkyloxy-, C_1-C_4 alkylthio-, C_1-C_4 alkyl-C(O)-, or C_1-C_4 alkyl-C(O)NH-;~~

each R^6 is, independently at each occurrence, H, C_{1-4} alkyl, $-(CH_2)_rC(O)OR^a$, $-(CH_2)_rS(O)_2NR^{7a}R^8$, or $-(CH_2)_rOR^a$;

each R^{6a} is, independently at each occurrence, H or C_{1-4} alkyl;

each R^7 is, independently at each occurrence, H, C_{1-6} alkyl, $-(CH_2)_n$-phenyl, (C_{1-6} alkyl)C(O)-, (C_{6-10} aryl)-C_{0-4} alkyl-C(O)-, (C_{3-6} cycloalkyl)-C_{0-4} alkyl-C(O)-, ~~(5-10 membered heteroaryl)-C_{0-4} alkyl-C(O)-,~~ (C_{1-4} alkyl)OC(O)-, (C_{6-10} aryl)-C_{0-4} alkyl-OC(O)-, (C_{1-4} alkyl)-C(O)O-(C_{1-4} alkyl)-OC(O)-, (C_{6-10} aryl)-C(O)O-(C_{1-4} alkyl)-OC(O)-, ~~(5-10 membered heteroaryl)-CH_2-OC(O)-,~~ (C_{1-6} alkyl)-NHC(O)-, (C_{6-10} aryl)-C_{0-4} alkyl-NHC(O)-,

~~(5-10 membered heteroaryl)-C_{0-4}-alkyl-NHC(O)-,~~ (C_{1-6} alkyl)-$S(O)_2$-, (C_{6-10} aryl)-(C_{0-4} alkyl)-$S(O)_2$-, ~~(5-10 membered heteroaryl)-C_{0-4}-alkyl-$S(O)_2$-,~~ (C_{1-6} alkyl)$_2$NC(O)-, phenyl-NHC(O)-, benzyl-NHC(O)-, (phenyl)(C_{1-6} alkyl)NC(O)-, or (benzyl)(C_{1-6} alkyl)NC(O)-, wherein said phenyl~~,~~ **and** aryl ~~and heteroaryl~~ are substituted with 0-2 R^f;

each R^{7a} is, independently at each occurrence, H, C_{1-4} alkyl substituted with 0-1 R^{7b} or 0-1 R^{7c}, -$(CH_2)_r$-C_{3-7} cycloalkyl substituted with 0-2 R^f, **or** -$(CH_2)_r$-phenyl substituted with 0-3 R^f, ~~or a -$(CH_2)_r$-5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted 0-3 R^f~~;

each R^{7b} is, independently at each occurrence, =O, OR^g, F, Cl, Br, I, CN, NO_2, -NR^7R^8, -$C(O)R^g$, -$C(O)OR^g$, -$NR^8C(O)R^g$, -$C(O)NR^8R^9$, -$NR^8C(O)NR^8R^9$, -$SO_2NR^8R^9$, -$NR^8SO_2NR^8R^9$, -NR^8SO_2-C_{1-4} alkyl, -$NR^8SO_2CF_3$, -NR^8SO_2-phenyl, -$S(O)_2CF_3$, -$S(O)_p$-C_{1-4} alkyl, -$S(O)_p$-phenyl, or -$(CF_2)_rCF_3$;

each R^{7c} is~~, independently at each occurrence,~~ C_{3-10} carbocycle substituted with 0-3 R^f; ~~or a 5-12 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted 0-3 R^f~~;

each R^8 is, independently at each occurrence, H, C_{1-6} alkyl, or -$(CH_2)_n$-phenyl;

each R^{8a} is, independently at each occurrence, H, OH, C_{1-6} alkyl, -$(CH_2)_n$-phenyl, (C_{1-6} alkyl)C(O)-, (C_{6-10} aryl)-C_{0-4} alkyl-C(O)-, (C_{3-6} cycloalkyl)-C_{0-4} alkyl-C(O)-, ~~(5-10 membered heteroaryl)-C_{0-4}-alkyl-C(O)-,~~ (C_{1-4} alkyl)OC(O)-, (C_{6-10} aryl)-C_{0-4} alkyl-OC(O)-, (C_{1-4} alkyl)-C(O)O-(C_{1-4} alkyl)-OC(O)-, (C_{6-10} aryl)-C(O)O-(C_{1-4} alkyl)-OC(O)-, ~~(5-10 membered heteroaryl)-CH_2-OC(O)-,~~ (C_{1-6} alkyl)-NHC(O)-, (C_{6-10} aryl)-C_{0-4} alkyl-NHC(O)-, ~~(5-10 membered heteroaryl)-C_{0-4}-alkyl-NHC(O)-,~~ (C_{1-6} alkyl)-$S(O)_2$-, (C_{6-10} aryl)-(C_{0-4} alkyl)-$S(O)_2$-,

~~(5-10 membered heteroaryl)-C_{0-4} alkyl-$S(O)_2$-,~~ C_{1-4} alkoxy, (C_{1-4} alkyl)C(O)O-, or (C_{6-10} aryl)-(C_{0-4} alkyl)-C(O)O-; wherein said phenyl~~,~~ and aryl ~~and heteroaryl~~ are substituted with 0-2 R^f;

~~alternatively, R^7 and R^8, or R^{7a} and R^8, when attached to the same nitrogen, combine to form a 5-10 membered heterocyclic ring consisting of carbon atoms and 0-2 additional heteroatoms selected from the group consisting of N, O, and $S(O)_p$;~~

each R^9 is, independently at each occurrence, H, C_{1-6} alkyl, or -$(CH_2)_n$-phenyl;

each R^{10} is, independently at each occurrence, H, C_{1-6} alkyl substituted with 0-2 R^{10a}, C_{2-6} alkenyl substituted with 0-2 R^{10a}, C_{2-6} alkynyl substituted with 0-2 R^{10a}, (C_{1-6} alkyl)C(O)-, (C_{3-6} cycloalkyl)C_{1-3} alkyl-C(O)-, (C_{3-6} cycloalkyl)C(O)-, phenyl-C(O)-, benzyl-C(O)-, benzyl-$S(O)_2$-, (C_{1-6} alkyl)NHC(O)-, (C_{1-6} alkyl)$_2$NC(O)-, phenyl-NHC(O)-, benzyl-NHC(O)-, (phenyl)(C_{1-6} alkyl)NC(O)-, (benzyl)(C_{1-6} alkyl)NC(O)-, (C_{1-6} alkyl)-$S(O)_2$-, phenyl-$S(O)_2$-, or -$(CH_2)_r$-C_{3-10} carbocycle substituted with 0-3 R^d~~, or -$(CH_2)_r$-5-10 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted with 0-3 R^d~~;

each R^{10a} is, independently at each occurrence, H, C_{1-4} alkyl, OR^a, Cl, F, Cl, Br, I, =O, CF_3, CN, NO_2, -C(O)R^a, -C(O)OR^a, -C(O)$NR^{7a}R^8$, or -$S(O)_pR^c$;

each R^{11} is, independently at each occurrence, H, =O, -$(CH_2)_r$-OR^a, F, Cl, Br, I, CN, NO_2, -$(CH_2)_r$-NR^7R^8, -C(O)R^a, -C(O)OR^a, -NR^8C(O)R^a, -NR^8C(O)OR^a, -C(O)$NR^{7a}R^8$, -NR^8C(O)NR^8R^9, -$SO_2NR^8R^9$, -$NR^8SO_2NR^8R^9$, -NR^8SO_2-C_{1-4} alkyl, -$NR^8SO_2CF_3$, -NR^8SO_2-phenyl, -$S(O)_2CF_3$, -$S(O)_p$-C_{1-4} alkyl, -$S(O)_p$-phenyl, -$(CF_2)_rCF_3$, C_{1-6} alkyl substituted with 0-2 R^{11a}, C_{2-6} alkenyl substituted with 0-2 R^{11a}, C_{2-6} alkynyl substituted with 0-2 R^{11a}, C_{1-6} alkyl substituted with 0-2 R^{11b}, C_{2-6} alkenyl substituted with 0-2 R^{11b}, or C_{2-6} alkynyl substituted with 0-2 R^{11b};

each R^{11a} is, independently at each occurrence, =O, OR^a, F, Cl, Br, I, CN, NO_2, -NR^7R^8, -C(O)R^a, -C(O)OR^a, -NR^8C(O)R^a, -C(O)$NR^{7a}R^8$, -NR^8C(O)NR^8R^9, -$SO_2NR^8R^9$, -$NR^8SO_2NR^8R^9$, -NR^8SO_2-C_{1-4} alkyl, -$NR^8SO_2CF_3$, -NR^8SO_2-phenyl,

$-S(O)_2CF_3$, $-S(O)_p$-C_{1-4} alkyl, $-S(O)_p$-phenyl, or $-(CF_2)_rCF_3$;

each R^{11b} is, independently at each occurrence, C_{3-10} carbocycle substituted with 0-3 R^d; or a 5-12 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted 0-3 R^d;

each R^{12} is, independently at each occurrence, OR^{12a}, $-C(O)NR^{7a}R^8$, $-(CH_2)_rCO_2R^{12a}$, $-(CH_2)_rSO_3H$, $-OSO_3H$, $-(CH_2)_rPO_3H$, $-OPO_3H_2$, $-PO_3H_2$, $-NHPO_3H_2$, $-NHCOCF_3$, $-NHSO_2CF_3$, $-CONHNHSO_2CF_3$, $-C(CF_3)_2OH$, $-SO_2NHR^{12a}$, $-CONHSO_2NHR^{12a}$, $-SO_2NHCOR^{12a}$, $-SO_2NHCO_2R^{12a}$, $-CONHSO_2R^{12b}$, $-NHSO_2R^{12b}$, $-CONHOR^{12b}$,





or

;

each R^{12a} is, independently at each occurrence, H, C_{1-6} alkyl, $-(CH_2)_r$-C_{3-10} carbocycle substituted with 0-3 R^d; or $-(CH_2)_r$-5-10 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted with 0-3 R^d;

each R^{12b} is, independently at each occurrence, C_1-C_6 alkyl substituted with 0-2 R^{12c}, C_2-C_6 alkenyl substituted with 0-2 R^{12c}, C_2-C_6 alkynyl substituted with 0-2 R^{12c}, $-(CH_2)_r$-C_3-C_{10} carbocycle substituted with 0-3 R^{12c}, or $-(CH_2)_r$-5-10 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted with 0-3 R^{12c};

each R^{12c} is, independently at each occurrence, H, F, Cl, Br, I, CF_3, OCF_3, CN, NO_2, OR^a, $-CO_2R^a$, $-NR^7R^8$, $-SO_2R^c$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl,

$-(CH_2)_r-C_{3-10}$ carbocycle substituted with 0-3 R^d; or $-(CH_2)_r$-5-10 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted with 0-3 R^d;

R^{13} is H or C_{1-4} alkyl;

R^{14} is H or C_{1-4} alkyl;

R^{16} is H, C_{1-4} alkyl, benzyl, C_{1-4} alkyl-C(O)-, C_{1-4} alkyl-$S(O)_2$-, or C_{1-4} alkyl-OC(O)-;

each R^a is, independently at each occurrence, H, C_{1-4} alkyl, $-(CH_2)_r-CO_2R^g$, $-(CH_2)_r-C_{3-7}$ cycloalkyl, **or** $-(CH_2)_r-C_{6-10}$ aryl, ~~**or $-(CH_2)_r$-5-10 membered heteroaryl,**~~ wherein said aryl ~~**or heteroaryl groups are**~~ **is** substituted with 0-2 R^f;

each R^b is, independently at each occurrence, CF_3, OH, C_{1-4} alkoxy, C_{1-6} alkyl, **or** $-(CH_2)_r-C_{3-10}$ carbocycle substituted with 0-2 R^d~~**, or $-(CH_2)_r$-5-10 membered heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$ and substituted with 0-2 R^d**~~;

each R^c is, independently at each occurrence, C_{1-4} alkyl, C_{6-10} aryl, ~~**5-10 membered heteroaryl,**~~ **or** (C_{6-10} aryl)-C_{1-4} alkyl~~**, or (5-10 membered heteroaryl)-C_{1-4} alkyl, wherein said aryl and heteroaryl groups are substituted with 0-2 R^d**~~;

each R^d is, independently at each occurrence, H, =O, OR^a, F, Cl, Br, I, CN, NO_2, $-NR^7R^8$, $-C(O)R^a$, $-C(O)OR^a$, $-NR^8C(O)R^a$, $-C(O)NR^{7a}R^8$, $-SO_2NR^8R^9$, $-NR^8SO_2NR^8R^9$, $-NR^8SO_2$-C_{1-4} alkyl, $-NR^8SO_2CF_3$, $-NR^8SO_2$-phenyl, $-S(O)_2CF_3$, $-S(O)_p$-C_{1-4} alkyl, $-S(O)_p$-phenyl, $-(CF_2)_rCF_3$, C_1-C_6 alkyl substituted with 0-2 R^e, C_2-C_6 alkenyl substituted with 0-2 R^e, or C_2-C_6 alkynyl substituted with 0-2 R^e;

each R^e is, independently at each occurrence, =O, OR^a, F, Cl, Br, I, CN, NO_2, $-NR^8R^9$, $-C(O)R^a$, $-C(O)OR^a$, $-NR^8C(O)R^a$, $-C(O)NR^{7a}R^8$, $-SO_2NR^8R^9$, $-NR^8SO_2NR^8R^9$, $-NR^8SO_2$-C_{1-4} alkyl, $-NR^8SO_2CF_3$, $-NR^8SO_2$-phenyl, $-S(O)_2CF_3$, $-S(O)_p$-C_{1-4} alkyl, $-S(O)_p$-phenyl, or $-(CF_2)_rCF_3$;

each R^f is, independently at each occurrence, H, =O, OR^g, F, Cl. Br, I, CN, NO_2, $-NR^8R^9$, $-C(O)R^g$, $-C(O)OR^g$, $-NR^8C(O)R^g$, $-C(O)NR^8R^9$, $-SO_2NR^8R^9$, $-NR^8SO_2NR^8R^9$, $-NR^8SO_2$-C_{1-4} alkyl, $-NR^8SO_2CF_3$, $-NR^8SO_2$-phenyl, $-S(O)_2CF_3$, $-S(O)_p$-C_{1-4} alkyl, $-S(O)_p$-phenyl, $-(CF_2)_rCF_3$, C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl;

each R^g is, independently at each occurrence, H, C_{1-6} alkyl, or $-(CH_2)_n$-phenyl;

n, at each occurrence, is selected from 0, 1, 2, 3, and 4;

p, at each occurrence, is selected from 0, 1, and 2; and

r, at each occurrence, is selected from 0, 1, 2, 3, and 4;

provided that A is phenyl or a 6-membered aromatic N-heterocycle, then ring A is not substituted ortho to the tetrahydroquinoline with OH, halogen, $-CO_2H$, $-C(O)O$-C_{1-4} alkyl, -O-phenyl, -O-benzyl, $-NR^7R^8$, $-CH_2OR^a$, haloalkyl, -S-C_{1-4} alkyl, or $-NHSO_2$-C_{1-4} alkyl.

3. (Currently amended) A compound according to Claim 2, wherein the compound is of Formula (Ib):



(Ib)

or a stereoisomer or a pharmaceutically acceptable salt or hydrate thereof, wherein:

B is phenyl substituted with 0-2 R^{11} and 0-1 R^{12};

R^1 is H, F, Cl, $-C(=NH)NH_2$, $-CH_2NH_2$, $-C(O)NR^{7a}R^8$, OMe, or CN;

R^4 is H, $-(CH_2)_r$-C_3-C_7 cylcoalkyl substituted with 0-2 R^{4b}, **or** $-(CH_2)_r$-phenyl substituted with 0-3 R^{4b}~~, or $-(CH_2)_r$-5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted with 0-3 R^{4b}~~;

each R^{4b} is, independently at each occurrence, H, OH, Cl, F, Cl, Br, CN, NO_2, CF_3, -$C(O)OR^a$, -SO_2R^c, -NR^7R^8, C_1-C_4 alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, C_3-C_6 cycloalkyl, C_1-C_4 haloalkyl, C_1-C_4 haloalkyloxy-, C_1-C_4 alkyloxy-, C_1-C_4 alkylthio-, C_1-C_4 alkyl-C(O)-, or C_1-C_4 alkyl-C(O)NH-;

R^5 is H, C_1-C_3 alkyl, or C_3-C_6 cycloalkyl;

each R^7 is, independently at each occurrence, H, C_{1-6} alkyl, or benzyl;

each R^{7a} is, independently at each occurrence, H, C_{1-4} alkyl substituted with 0-1 R^{7b} or 0-1 R^{7c}, -$(CH_2)_r$-C_{3-7} cycloalkyl substituted with 0-1 R^f, **or** -$(CH_2)_r$-phenyl substituted with 0-2 R^f~~, or a -$(CH_2)_r$- 5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted 0-2 R^f~~;

each R^{7b} is, independently at each occurrence, OR^g, F, CN, -NR^7R^8, -$C(O)R^g$, -$C(O)OR^g$, -$NR^8C(O)R^g$, -$C(O)NR^8R^9$, -$SO_2NR^8R^9$, or -NR^8SO_2-C_{1-4} alkyl;

each R^{7c} is~~, independently at each occurrence,~~ C_{3-7} cycloalkyl substituted with 0-1 R^f, **or** phenyl substituted with 0-2 R^f~~, or a 5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted 0-2 R^f~~;

each R^8 is, independently at each occurrence, H, C_{1-6} alkyl, or benzyl;

each R^9 is, independently at each occurrence, H, C_{1-6} alkyl, or benzyl;

each R^{11} is, independently at each occurrence, H, F, -$(CH_2)_r$-OR^a, CN, -$(CH_2)_r$-NR^7R^8, -$C(O)OR^a$, -$NR^8C(O)R^a$, -$NR^8C(O)OR^a$, -$C(O)NR^{7a}R^8$, -$NR^8C(O)NR^8R^9$, -$SO_2NR^8R^9$, or -NR^8SO_2-C_{1-4} alkyl;

R^{12} is -$C(O)NR^{7a}R^8$, -$(CH_2)_rCO_2R^{12a}$, -SO_2NHR^{12a}, -$CONHSO_2NHR^{12a}$, -SO_2NHCOR^{12a}, -$SO_2NHCO_2R^{12a}$, -$CONHSO_2R^{12b}$, -$NHSO_2R^{12b}$, -$CONHSO_2R^{12b}$, -$CONHOR^{12b}$, or -$(CH_2)_r$-5-tetrazolyl-;

each R^{12a} is, independently at each occurrence, H or C_{1-6} alkyl;

each R^{12b} is, independently at each occurrence, C_1-C_4 alkyl substituted with 0-1 R^{12c}, C_2-C_4 alkenyl substituted with 0-1 R^{12c}, C_2-C_4 alkynyl substituted with 0-1 R^{12c}, -$(CH_2)_r$-C_3-C_7 carbocycle substituted with 0-2 R^{12c}, or -$(CH_2)_r$-5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted with 0-2 R^{12c};

each R^{12c} is, independently at each occurrence, H, F, Cl, Br, I, CF_3, OCF_3, CN, NO_2, OR^a, -CO_2R^a, -NR^7R^8, -SO_2R^c, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, -$(CH_2)_r$-C_{3-10} carbocycle substituted with 0-3 R^d; or -$(CH_2)_r$-5-10 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$, and substituted with 0-3 R^d;

R^{13} is H or C_1-C_4 alkyl;

each R^a is, independently at each occurrence, H, C_{1-4} alkyl, -$(CH_2)_r$-CO_2R^g, -$(CH_2)_r$-C_{3-7} cycloalkyl, **or** -$(CH_2)_r$-C_{6-10} aryl~~, or -$(CH_2)_r$-5-10 membered heteroaryl, wherein said aryl or heteroaryl groups are substituted with 0-2 R^f~~;

each R^f is, independently at each occurrence, H, =O, OR^g, F, Cl, Br, CF_3, CN, NO_2, -NR^8R^9, -$C(O)R^g$, -$C(O)OR^g$, -$NR^8C(O)R^g$, -$C(O)NR^8R^9$, -$SO_2NR^8R^9$, -NR^8SO_2-C_{1-4} alkyl, -$NR^8SO_2CF_3$, -$S(O)_2CF_3$, -$S(O)_p$-C_{1-4} alkyl, C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl;

each R^g is, independently at each occurrence, H or C_{1-4} alkyl;

p, at each occurrence, is selected from 0, 1, and 2;

r, at each occurrence, is selected from 0, 1, 2, 3, and 4; and

provided ring A is not substituted ortho to its attachment to the tetrahydroquinoline with OH, -CO_2H, -$C(O)O$-C_{1-4} alkyl, O-phenyl, O-benzyl, -NR^7R^8, or -$NHSO_2C_{1-4}$ alkyl.

4. (Original) A compound according to Claim 3, wherein:

A is phenyl substituted with 0-2 R^{11};

B is phenyl substituted with 0-2 R^{11} and 0-1 R^{12};

R^1 is $-C(=NH)NH_2$, $-C(=O)NH_2$, $-CH_2NH_2$, or OMe;

R^4 is phenyl substituted with 0-1 R^{4b};

R^{4b} is H, OH, or F;

R^5 is H, Me, Et, or Pr;

each R^{11} is, independently at each occurrence, H, F, OH, OMe, CN, $-NH_2$, $-CH_2OH$, $-CO_2H$, $-CO_2Me$, -NHCOMe, -NHCOEt, -NHCOPr, -NHCO(i-Pr), -NHCO(i-Bu), -NHCO(cyclopropyl), -NHCO(phenyl), $-NHCO(2-CO_2H\text{-phenyl})$, $-NHCO(3-CO_2H\text{-phenyl})$, $-NHCO(4-CO_2H\text{-phenyl})$, $-NHCO(3,5-(CO_2H)_2\text{-phenyl})$-, $-NHCO(3,5-(CF_3)_2\text{-phenyl})$, $-NHCO(3\text{-Me-}5-CO_2H\text{-phenyl})$, $-NHCO(3\text{-(t-Bu)-}5-CO_2H\text{-phenyl})$, $-NHCO(3-CONH_2\text{-}5-CO_2H\text{-phenyl})$, $-NHCO(3-NH_2\text{-}5-CO_2H\text{-phenyl})$, -NHCO(benzyl), -NHCO(phenethyl), -NHCO(phenylpropyl), -NHCO[2-(2-pyridyl)-ethyl], -NHCO(tetrazol-5-yl), $-NHCOCH_2$(tetrazol-5-yl), $-NHCO(CH_2)_2$(tetrazol-5-yl), $-CONH_2$, -CONHMe, -CONH(i-Pr), -CONH(i-Bu), -CONH(t-Bu), -CONH(benzyl), -CONH(phenethyl), -CONH(phenylpropyl), -CONH[2-(2-pyridyl)-ethyl], -NHCONHMe, -NHCONHEt, $-NHCH_2CO_2H$, $-NHCOCO_2H$, $-NHCOCH_2CO_2H$, $-NHCO(CH_2)_2CO_2H$, $-NHCO(CH_2)_3CO_2H$, $-NHSO_2Me$, $-NHSO_2Et$, or $-CH_2NMe_2$;

R^{12} is $-CO_2H$, $-CH_2(CO_2H)$, $-CO_2Me$, $-SO_2NH_2$, or $-CONH_2$;

R^{13} is H or Me; and

provided ring A is not substituted ortho to its attachment to the tetrahydroquinoline with OH, $-CO_2H$, $-CO_2Me$, $-NH_2$, or $-NHSO_2C_{1\text{-}4}$ alkyl.

5. (Original) A compound according to Claim 4, wherein:

A is 1,2-phenylene, 4-OMe-1,2-phenylene, $3-CO_2H$-1,2-phenylene, 4-OMe-5-OH-1,2-phenylene, $5-CH_2OH$-1,2-phenylene, 5-NHCOMe-1,2-phenylene, 5-phenylcarbamoyl-1,2-phenylene, 5- benzylcarbamoyl-1,2-phenylene, 5-phenethylcarbamoyl-1,2-phenylene, 5-(3-phenylpropylcarbamoyl)-1,2-phenylene,

5-[2-(2-pyridyl)ethylcarbamoyl]-1,2-phenylene, 5-NHCO(i-Bu)-1,2-phenylene,

1,3-phenylene, 6-OMe-1,3-phenylene, 6-F-1,3-phenylene, 5-NH_2-1,3-phenylene,

5-NHCOMe-1,3-phenylene, 5-NHCOEt-1,3-phenylene, 5-NHCOPr-1,3-phenylene,

5-NHCO(i-Pr)-1,3-phenylene, 5-NHCO(i-Bu)-1,3-phenylene,

5-NHCO(cyclopropyl)-1,3-phenylene, 5-NHCONHEt-1,3-phenylene,

5-$NHCOCO_2H$-1,3-phenylene, 5-$NHCOCH_2CO_2H$-1,3-phenylene,

5-$NHCO(CH_2)_2CO_2H$-1,3-phenylene, 5-$NHCO(CH_2)_3CO_2H$-1,3-phenylene,

5-NHCO(phenyl)-1,3-phenylene, 5-NHCO(benzyl)-1,3-phenylene,

5-$NHCO$(2-CO_2H-phenyl)-1,3-phenylene, 5-$NHCO$(3-CO_2H-phenyl)-1,3-phenylene,

5-$NHCO$(4-CO_2H-phenyl)-1,3-phenylene,

5-$NHCO$(3,5-$(CO_2H)_2$-phenyl)-1,3-phenylene,

5-$NHCO$(3,5-$(CF_3)_2$-phenyl)-1,3-phenylene,

5-$NHCO$(3-Me-5-CO_2H-phenyl)-1,3-phenylene,

5-$NHCO$(3-(t-Bu)-5-CO_2H-phenyl)-1,3-phenylene,

5-$NHCO$(3-$CONH_2$-5-CO_2H-phenyl)-1,3-phenylene,

5-$NHCO$(3-NH_2-5-CO_2H-phenyl)-1,3-phenylene,

5-NHCO(tetrazol-5-yl)-1,3-phenylene, 5-$NHCOCH_2$(tetrazol-5-yl)-1,3-phenylene,

5-$NHCO(CH_2)_2$(tetrazol-5-yl)-1,3-phenylene, 5-$NHSO_2Et$-1,3-phenylene,

5-$NHCH_2CO_2H$-1,3-phenylene, or 3-CO_2H-1,4-phenylene;

B is 2-CO_2H-phenyl, 4-CO_2H-phenyl, 2-SO_2NH_2-phenyl,

3-$CH_2(CO_2H)$-phenyl, 2,4-$(CO_2H)_2$-phenyl, 2,4-$(CO_2Me)_2$-phenyl,

2,4-$(CONH_2)_2$-phenyl, 2-CO_2H-4-CO_2Me-phenyl, 2-CO_2H-4-NH_2-phenyl,

2-CO_2H-4-CN-phenyl, 2-CO_2H-4-OMe-phenyl, 2-CO_2H-4-NHAc-phenyl,

2-CO_2H-4-$CONH_2$-phenyl, 2-CO_2H-4-CONH(i-Pr)-phenyl,

2-CO_2H-4-C(O)NH(i-Bu)-phenyl, 2-CO_2H-4-C(O)NH(t-Bu)-phenyl,

2-CO_2H-4-NHCOMe-phenyl, 2-CO_2H-4-NHCONHMe-phenyl,

2-CO_2H-4-CH_2NMe_2-phenyl, or 2-CO_2H-4-$NHSO_2Me$-phenyl;

R^1 is -$C(=NH)NH_2$, -$C(=O)NH_2$, -CH_2NH_2, or OMe;

R^4 is phenyl, 4-OH-phenyl or 4-F-phenyl;

R^5 is H, Me, Et, or Pr; and

R^{13} is H or Me.

6. (Original) A compound of Claim 1 selected from:

2'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-isobutylcarbamoyl-biphenyl-2-carboxylic acid;

2'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-isobutylcarbamoyl-5'-hydroxy-4'-methoxy-biphenyl-2-carboxylic acid;

2'-[6-carbamimidoyl-4-(4-hydroxy-phenyl)-1,2,3,4-tetrahydro-quinolin-2-yl]-5'-hydroxy-4-isobutylcarbamoyl-4'-methoxy-biphenyl-2-carboxylic acid;

2'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2,4-dicarboxylic acid dimethyl ester;

2'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2,4-dicarboxylic acid;

2'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2-carboxylic acid;

2'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-4-carboxylic acid;

2'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2,4-dicarboxylic acid dimethyl ester;

2'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2,4-dicarboxylic acid;

3'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-isobutylcarbamoyl-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-t-butylcarbamoyl-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2,4-dicarboxylic acid;

3'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2-carboxylic acid;

4-phenyl-2-(2'-sulfamoyl-biphenyl-3-yl)-1,2,3,4-tetrahydro-quinoline-6-carboxamidine;

4-methyl-4-phenyl-2-(2'-sulfamoyl-biphenyl-3-yl)-1,2,3,4-tetrahydro-quinoline-6-carboxamidine;

3'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2,4-dicarboxylic acid 4-methyl ester;

3'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2,4-dicarboxylic acid diamide;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2,4-dicarboxylic acid;

3'-(6-carbamimidoyl-4-ethyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2,4-dicarboxylic acid;

3'-(6-carbamimidoyl-4-propylyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2,4-dicarboxylic acid;

4-amino-3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-(3-methyl-ureido)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-methanesulfonylamino-biphenyl-2-carboxylic acid;

4-acetylamino-3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-cyano-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2,4-dicarboxylic acid 4-methyl ester;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-methylcarbamoyl-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-isopropylcarbamoyl-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-t-butylcarbamoyl-biphenyl-2-carboxylic acid;

3'-[6-carbamimidoyl-4-(4-fluoro-phenyl)-4-methyl-1,2,3,4-tetrahydro-quinolin-2-yl]-4-carbamoyl-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-dimethylaminomethyl-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-3-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-biphenyl-2-carboxylic acid;

5'-amino-3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-biphenyl-2-carboxylic acid;

5'-amino-3'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2-carboxylic acid;

5'-acetylamino-3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(3-methyl-butyrylamino)-biphenyl-2-carboxylic acid;

4-carbamoyl-3'-(6-carbamoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2-carboxylic acid;

4-carbamoyl-3'-(6-methoxy-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-biphenyl-2-carboxylic acid;

3'-(6-aminomethyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(3-methyl-butyrylamino)-biphenyl-2-carboxylic acid;

3'-(6-aminomethyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(3-methyl-butyrylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(2-methylpropanoylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(n-propanoylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(cyclopropylcarbonylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-methoxyl-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(butyrylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-4'-methoxy-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-4'-fluoro-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(2-carboxyproacetylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(carboxycarbonylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(benzoylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(2-methylpropanoylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(2-phenylacetylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-(4-fluorophenyl)-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(2-methylpropanoylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(3-carboxypropanoylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(4-carboxybenzoylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(3-carboxybenzoylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(2-carboxybenzoylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(carboxymethylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(3,5-biscarboxybenzoylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-[(5-tetrazolyl)methylcarbonylamino]-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(4-carboxybutyrylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-[(5-tetrazoyl)carbonylamino]-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(3,5-bisfluorobenzoylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(3-amino-5-carboxybenzoylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-[2-(5-tetrazolyl)ethylcarbonylamino]-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(3-carboxy-5-methylbenzoylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(3-carboxy-5-t-butylbenzoylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(3-aminocarbonyl-5-carboxybenzoylamino)-biphenyl-2-carboxylic acid;

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(ethylaminocarbonylamino)-biphenyl-2-carboxylic acid; and

3'-(6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-2-yl)-4-carbamoyl-5'-(ethylsulfonylamino)-biphenyl-2-carboxylic acid;

or a stereoisomer or a pharmaceutically acceptable salt or hydrate thereof.

7. (Original) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt or hydrate thereof.

8. (Original) A method for treating thromboembolic disorders, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt or hydrate thereof.

9. (Original) A method according to Claim 8, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

10. (Original) A method according to Claim 9, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.

11. (Withdrawn) A method for treating inflammatory disorders, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt or hydrate thereof.

12. (Withdrawn) A method according to Claim 11, wherein the inflammatory disorder is selected from the group consisting of sepsis, acute respiratory dystress syndrome, and systemic inflammatory response syndrome.

13. (Original) A method of treating a patient in need of thromboembolic disorder treatment, comprising: administering a compound of Claim 1 or a pharmaceutically acceptable salt or hydrate thereof in an amount effective to treat a thromboembolic disorder.

14. (Original) A method, comprising: administering a compound of Claim 1 or a pharmaceutically acceptable salt or hydrate thereof in an amount effective to treat a thromboembolic disorder.

15-23. (Canceled)

24. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 2 or a pharmaceutically acceptable salt or hydrate thereof.

25. (New) A method for treating thromboembolic disorders, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 2 or a pharmaceutically acceptable salt or hydrate thereof.

26. (New) A method according to Claim 25, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

27. (New) A method according to Claim 26, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.

28. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 3 or a pharmaceutically acceptable salt or hydrate thereof.

29. (New) A method for treating thromboembolic disorders, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 3 or a pharmaceutically acceptable salt or hydrate thereof.

30. (New) A method according to Claim 29, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

31. (New) A method according to Claim 30, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.

32. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 4 or a pharmaceutically acceptable salt or hydrate thereof.

33. (New) A method for treating thromboembolic disorders, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 4 or a pharmaceutically acceptable salt or hydrate thereof.

34. (New) A method according to Claim 33, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders,

venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

35. (New) A method according to Claim 34, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.

36. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 5 or a pharmaceutically acceptable salt or hydrate thereof.

37. (New) A method for treating thromboembolic disorders, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 5 or a pharmaceutically acceptable salt or hydrate thereof.

38. (New) A method according to Claim 37, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

39. (New) A method according to Claim 38, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.

40. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 6 or a pharmaceutically acceptable salt or hydrate thereof.

41. (New) A method for treating thromboembolic disorders, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 6 or a pharmaceutically acceptable salt or hydrate thereof.

42. (New) A method according to Claim 41, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

43. (New) A method according to Claim 42, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein

thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis.